This study examined left-ventricular assist device (LVAD) patients with pre-LVAD ventricular arrhythmias (VAs) to determine the rate of recurrent post-LVAD VAs and the impact of pre-LVAD atrial fibrillation (AF) on recurrent post-LVAD VAs. Medical records of 195 consecutive LVAD patients were reviewed. Descriptive statistics were generated and Cox proportional hazard models were used to assess the association of clinical variables with the time to recurrent VA. Forty-seven percent of 195 CHF patients who received LVAD-manifested significant VAs prior to LVAD implant (82% Heartmate II, 14% HVAD, 4% other; median follow-up = 17 months), 41% of whom manifested recurrent post-LVAD VAs. Pre-LVAD AF was associated with recurrent VAs (hazard ratio = 3.73; 95% CI 1.33, 10.48; p = 0.012). Recurrent VAs were associated with increased mortality (hazard ratio = 3.06; 95% CI 1.17, 7.98; p = 0.023). A history of AF is prevalent in over half of LVAD patients with recurrent VAs and is associated with time to recurrence of VA.
Ventricular arrhythmias Left ventricular assist devices Cardiac outcomes Atrial fibrillation
This is a preview of subscription content, log in to check access.
We would like to acknowledge our research coordinator Paul Gonzalez, who assisted with the data collection.
Compliance with Ethical Standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Columbia University IRB-AAAM2607) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of Interest
The authors declare that they have no conflicts of interest.
Enriquez, A. D., et al. (2014). Clinical impact of atrial fibrillation in patients with the HeartMate II left ventricular assist device. Journal of the American College of Cardiology, 64(18), 1883–1890.CrossRefGoogle Scholar
Brenyo, A., et al. (2012). Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients. Journal of Cardiovascular Electrophysiology, 23(5), 515–520.CrossRefGoogle Scholar
Oswald, H., et al. (2010). Implantable defibrillator therapy for ventricular tachyarrhythmia in left ventricular assist device patients. European Journal of Heart Failure, 12(6), 593–599.CrossRefGoogle Scholar
Andersen, M., et al. (2009). Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (HeartMate II). The Journal of Heart and Lung Transplantation, 28(7), 733–735.CrossRefGoogle Scholar
Garan, A. R., et al. (2013). Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention? Journal of the American College of Cardiology, 61(25), 2542–2550.CrossRefGoogle Scholar
Hickey, K. T., et al. (2016). Atrial fibrillation in patients with left ventricular assist devices: Incidence, Predictors, and Clinical Outcomes. JACC: Clinical Electrophysiology, 2(7), 793–798.PubMedGoogle Scholar
Efimova, E., et al. (2017). Predictors of ventricular arrhythmia after left ventricular assist device implantation: a large single-center observational study. Heart Rhythm, 14(12), 1812–1819.CrossRefGoogle Scholar
Refaat, M., et al. (2008). Ventricular arrhythmias after left ventricular assist device implantation. Pacing and Clinical Electrophysiology, 31(10), 1246–1252.CrossRefGoogle Scholar
Kadado, A. J., Akar, J. G., & Hummel, J. P. (2018). Arrhythmias after left ventricular assist device implantation: incidence and management. Trends in Cardiovascular Medicine, 28(1), 41–50.CrossRefGoogle Scholar
Deshmukh, A., et al. (2017). Atrial arrhythmias and electroanatomical remodeling in patients with left ventricular assist devices. Journal of the American Heart Association, 6(3). https://doi.org/10.1161/JAHA.116.005340.
Hottigoudar, R. U., et al. (2013). Catheter ablation of atrial flutter in patients with left ventricular assist device improves symptoms of right heart failure. Congestive Heart Failure, 19(4), 165–171.CrossRefGoogle Scholar
Somberg, J. C., et al. (2004). Enhancement of myocardial vulnerability by atrial fibrillation. American Journal of Therapeutics, 11(1), 33–43.CrossRefGoogle Scholar
Kotecha, D., et al. (2017). Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. Journal of the American College of Cardiology, 69(24), 2885–2896.CrossRefGoogle Scholar
Packer, D. L., et al. (2018). Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: study rationale and design. American Heart Journal, 199, 192–199.CrossRefGoogle Scholar
Bardy, G. H., et al. (2005). Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The New England Journal of Medicine, 352(3), 225–237.CrossRefGoogle Scholar
Moss, A. J., et al. (2009). Cardiac-resynchronization therapy for the prevention of heart-failure events. The New England Journal of Medicine, 361(14), 1329–1338.CrossRefGoogle Scholar
Moss, A. J., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England Journal of Medicine, 346(12), 877–883.CrossRefGoogle Scholar
Makki, N., et al. (2015). Meta-analysis of the relation of ventricular arrhythmias to all-cause mortality after implantation of a left ventricular assist device. The American Journal of Cardiology, 116(9), 1385–1390.CrossRefGoogle Scholar
Kirklin, J. K., et al. (2017). Eighth annual INTERMACS report: special focus on framing the impact of adverse events. The Journal of Heart and Lung Transplantation, 36(10), 1080–1086.CrossRefGoogle Scholar
Enriquez, A. D., et al. (2013). The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices. Circulation. Arrhythmia and Electrophysiology, 6(4), 668–674.CrossRefGoogle Scholar